Digestive Cancer
Conditions
Keywords
PIPAC, oxaliplatin, peritoneal metastases
Brief summary
Current curative treatment of digestive peritoneal carcinomatosis consists of complete cytoreduction surgery associated with intraperitoneal chemotherapy. This treatment has important limits: a high morbimortality and the impossibility of repeating the sessions. The majority of patients are therefore treated with systemic chemotherapy, which despite its progress, remains palliative. Pressurized Intraperitoneal aerosol chemotherapy (PIPAC) has many advantages: under laparoscopy, low morbidity, good intratumoral penetration of cytotoxics, possibility of repeating the sessions and low financial cost. Therefore, the investigator propose a phase 1 study, in colorectal and stomach cancer, with oxaliplatin doses escalation in Pressurized Intraperitoneal aerosol chemotherapy. It would allow a better tumor response, with potentially few risks and thus improve survival in patients with digestive peritoneal carcinoses, increasing access to cytoreductive surgery.
Detailed description
The objective of this study is to determine the maximum tolerated dose (mtd) of oxaliplatin to be used during PIPAC. Study design is a phase I/II, multicentre, non-comparative, non-randomised dose escalation clinical trial. The phase I study will consist of a 3 by 3 dose escalation according to modified fibonacci dose escalation, starting at the current PIPAC dose (i.e. 90mg/m2), up to a maximum dose of 300mg/m2, corresponding to the current Intraperitoneal chemohyperthermia. Each patient may receive up to 5 PIPAC sessions ; DLT period will be from the first day (D1) of the first PIPAC session until the end of the second PIPAC session, including the interval chemotherapy (i.e. D-1 of the 3rd CIPPA session), i.e. 4 to 6 weeks later ; Phase II study is an extension cohort at the recommended dose determined in the Phase I study. It will be a multi-centre, single-arm study and will analyse overall patient survival and secondary resectability rates with complete cytoreductive surgery and intraperitoneal chemohyperthermia. It will be conducted in approximately 20 patients treated at the recommended dose and followed for 2 years.
Interventions
DRUG5-Fluorouracil
Presentation: Concentrated solution for concentrated infusion in vials containing 250 mg, 500 mg, 1 g and 5 g, in 5 ml, 10 ml, 20 ml and 100 ml respectively, providing a 50 mg / ml solution. Dosage: 400mg / m2. Administration: IV. Day of administration: between 1 h and 24 h before PIPAC.
DRUGL-Folinic acid
Presentation: lyophilisate for parenteral use, dosed at 25 mg, and in the form of a solution for injection by IM or IV dosed at 25 mg / 2.5 ml. Dosage: 20mg / m2. Administration: IV. Day of administration: between 1 h and 24 h before PIPAC.
DRUGOxaliplatin
Concentrated solution for infusion dosed with 50 mg and 100 mg. Dosage: depending on the dose range assigned to inclusion (from 90mg / m2 to 300mg / m2). Administration: the solution is packaged in a syringe which is subsequently used for injection and not in a conventional bag. The product is administered in a high-pressure injector, during the PIPAC. Day of administration : J1 of PIPAC
Sponsors
Institut Cancerologie de l'Ouest
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1\. Patient age ≥ 18 years 2. Histological or cytological diagnosis or suspicion of peritoneal carcinosis of colorectal, gastric or bowel origin 3. Having previously received at least 3 months of systemic chemotherapy for metastatic disease (type of chemotherapy left to the discretion of each investigator). Patients who received bevacizumab (Avastin®) can be included if and only if the time between the last treatment administered and the first PIPAC received is at least 4 weeks 4. ECOG performance index \< or = 2 5. Life expectancy\> 3 months 6. Peripheral neuropathy grade ≤ 1 7. Hematological function: Hemoglobin ≥ 9 g / dL, leukocytes ≥ 4000 / mm3, PNN ≥ 1500 / mm3, platelets ≥ 100 000 / mm3 8. Creatinine clearance\> 50 mL / min (cockcroft and Gault formula) 9. Hepatic function: Total bilirubin ≤ 1.5 x ULN, ASAT and ALAT ≤ 3 x ULN, Alkaline phosphatases ≤ 3 x ULN 10 . Patients with no known or partial deficiency of Dihydropyrimidine dehydrogenase (i.e. DPD) 11. Effective contraception for women of childbearing age 13. Informing the patient and obtaining free, informed and written consent signed by the patient and his / her investigator. 14\. Affiliated subject or beneficiary of the social security scheme.
Exclusion criteria
1. Patients who received bevacizumab (Avastin®) less than 4 weeks ago can not be included 2. Extra-peritoneal metastases, except for less than 3 pulmonary nodules (each size \<5mm) 3. Known hypersensitivity to Oxaliplatin 4. Known complete dihydropyrimidine dehydrogenase (i.e. DPD) deficiency 5. Peripheral neuropathy Grade \>1 due to or not with Oxaliplatin previously used 6. Active or other serious underlying disease that may prevent the patient from receiving treatment 7. Intracranial or intraocular hypertension (ongoing at the time of inclusion) 8. Severe or Severe Heart Failure (ongoing at the time of inclusion) 9. Complete intestinal obstruction (ongoing at the time of inclusion) 10. Other concurrent cancer or history of cancer other than in situ cancer of treated cervix or basal cell carcinoma or squamous cell carcinoma 11. Pregnant or nursing women 12. Persons deprived of their liberty or under guardianship or unable to give their consent 13. Inability to submit to medical follow-up of the trial for geographical, social or psychological reasons 14. Long-term corticosteroids (duration\> 3 months), except for weaning for at least 3 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximal Tolerated Dose | 8 to 12 weeks | Maximal tolerated dose 3x3 patients inclusion(modified fibonacci dose escalation) |
| Recommanded dose for the extension phase | 8 to 12 weeks | Dose level below the maximum tolerated dose |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cumulative toxicity after the end of the PIPAC sessions received (maximum 5) at the same dose level | 24 months after the last PIPAC received | with CTC-AE scale |
| Overall survival | 24 months after the last PIPAC received | Median overall survival at the end of the study |
| Progression-Free Survival | 12 months after the last PIPAC received | Median PFS, time between the first PIPAC received and progression or death in absence of progression |
Countries
France
Outcome results
None listed